A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety, tolerability and effectiveness of Oral
CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small
lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to
two or more lines of established therapy or for whom no other treatment options are
available.